Non-Alcoholic Steatohepatitis Epidemiology

Nonalcoholic Steatohepatitis (NASH) is the gradual form of liver injury, which carries a risk of progressive fibrosis, cirrhosis, and end-stage liver disease. It is a progressive form of non-alcoholic fatty liver disease (NAFLD) that is caused by the fat buildup in the liver. So, when this buildup leads to inflammation and damage, then it is called NASH. The disease leads to liver scarring; it is a life-threatening condition known as cirrhosis.

NASH Market

NASH falls under the category of silent diseases that has very few or no symptoms typically because it does not cause any symptoms until it is too late. In the early period, patients did not complain about anything specific. Even with the advancing fibrosis, the disease may not have any specific problems. However, in the later stages, patients may start developing some non-specific symptoms.

The classification of fibrosis stages of NASH is as follows:

• No Fibrosis (F0)
• NASH Fibrosis (F1–F3)
• NASH Cirrhosis (F4). 

NASH has been defined to keep progressing from early stages (F0 and F1) to advanced stages (F2–F4) over time, according to various studies. The development of NASH with cirrhosis increases the risk of NASH Decompensated Cirrhosis and ultimately lead to death.

·         DelveInsight has covered the exhaustive NASH epidemiology and market research report that covers major markets- US, Europe (Germany, Italy, Spain, France and the United Kingdom,) and Japan. The critical points of the report are:-

·         An increase in obesity, diabetes population will significantly increase NAFLD prevalent cases with the CAGR of 1.02% for the study period, i.e. 2017–2030 in the 7MM.

·         Of all the prevalent cases of NAFLD in the 7MM, approximately 19% of the population fulfilled the criteria for NASH, and these cases are expected to increase throughout the study period [2017–2030]. 

NASH Epidemiology and Market

·         The highest NASH prevalence was observed in the United States, with more than 17 million cases in 2017 that accounted close to 50% of the total prevalent cases, followed by Japan.  

On the other hand, it is assessed that among the European countries, Germany accounted for the highest prevalent population, followed by Italy. Among all the 7MM countries, Spain had the lowest prevalent population.

DelveInsight’s estimations suggest that of the total diagnosed patients in the United States, F4 accounts for the maximum number in the patient pool (~60%), while F0 had least reported cases. This is due to the nature of the disease to keep on progressing over time, thereby leading to the addition of several patients from early stages of NASH to those in advanced stages.

The report includes the epidemiology segmentation based on Total Prevalent Cases of Non-Alcoholic Fatty Liver Disease in the 7MM, Total Prevalent cases of Nonalcoholic Steatohepatitis in the 7MM and Nonalcoholic Steatohepatitis Segmentation by Fibrosis Stage in the 7MM for the study period of 2017– 2030.